Back to Lung Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT05110118

NCT05110118
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You are a healthy male volunteer
  • You are between 18 and 45 years old
  • You weigh between 50 kg (about 110 lbs) and 100 kg (about 220 lbs)
  • Your Body Mass Index (BMI) — a measure of body weight relative to height — is between 19.0 and 26.0 (confirm with trial site if unsure of your BMI)

Who may not be able to join:

  • You have been diagnosed with, or have a history of, any significant illness or medical condition
  • You have a personal history of cancer of any kind
  • You have a history of high blood pressure, or your blood pressure measured at the screening appointment was too high (above 140/90 mmHg)
  • You have donated blood in the 3 months before the study treatment would be given
  • You have been exposed to antibody-based treatments in the 12 months before the study treatment would be given (confirm with trial site if unsure)
  • You have previously received any treatment that targets a protein called VEGF, which is involved in blood vessel growth (confirm with trial site if unsure)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Shandong Boan Biotechnology Co., Ltd
Registry
clinicaltrials_gov
Start date
4 August 2020
Est. completion
13 January 2021

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Area under the plasma concentration-time curve from time zero to the last measurable concentration(AUC0-t); Area under the plasma concentration-time curve from time zero to infinity(AUC0-∞); Maximum (peak) plasma concentration(Cmax); Chloride(CL); Terminal elimination half-life(t1/2); Apparent volume of distribution(Vd)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov